Combined yeast β-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55

Cancer Research

Volumn 67, Issue 15, 2007, Pages 7421-7430

  Li, Bing ^a   Allendorf, Daniel J ^a   Hansen, Richard ^a   Marroquin, Jose ^a   Cramer, Daniel E ^a   Harris, Claire L ^b   Yan, Jun ^a,c  

^a University of Louisville School of Medicine   (United States)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCAN; CETUXIMAB; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5A; DECAY ACCELERATING FACTOR; DECAY ACCELERATING FACTOR MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARCINOMA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; REGULATORY MECHANISM; SCID MOUSE; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD55; BETA-GLUCANS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CHEMOTAXIS, LEUKOCYTE; COMPLEMENT C3A; COMPLEMENT C5A; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED ICR; MICE, SCID; NEUTROPHIL INFILTRATION; OVARIAN NEOPLASMS; SACCHAROMYCES CEREVISIAE; TUMOR CELLS, CULTURED;

EID: 34547619005     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1465     Document Type: Article

References (45)

1. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147-57.
2. Ross JS, Schenkein DP, Pietrusko R, et al. Targeted therapies for cancer 2004. Am J Clin Pathol 2004;122:598-609.
3. Thornton BP, Vetvicka V, Pitman M, Goldman RC, Ross GD. Analysis of the sugar specificity and molecular location of the h-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J Immunol 1996;156:1235-46.
4. Xia Y, Vetvicka V, Yan J, et al. The β-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J Immunol 1999;162:2281-90.
5. Li B, Allendorf DJ, Hansen R, et al. Yeast β-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway. J Immunol 2006;177:1661-9.
6. Yan J, Allendorf DJ, Brandley B. Yeast whole glucan particle (WGP) h-glucan in conjunction with antitumour monoclonal antibodies to treat cancer. Expert Opin Biol Ther 2005;5:691-702.
7. Yan J, Vetvicka V, Xia Y, et al. β-Glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). J Immunol 1999;163:3045-52.
8. Hong F, Hansen RD, Yan J, et al. β-Glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res 2003;63:9023-31.
9. Hong F, Yan J, Baran JT, et al. Mechanism by which orally administered β-1,3-glucans enhance the tumor-icidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol 2004;173:797-806.
10. Allendorf DJ, Yan J, Ross GD, et al. C5a-mediated leukotriene B4-amplified neutrophil chemotaxis is essential in tumor immunotherapy facilitated by anti-tumor monoclonal antibody and β-lucan. J Immunol 2005;174:7050-6.
11. Cheung NK, Modak S. Oral (1→3),(1→4)-β-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res 2002;8:1217-23.
12. Cheung NK, Modak S, Vickers A, Knuckles B. Orally administered β-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother 2002;51:557-64.
13. Modak S, Koehne G, Vickers A, O'Reilly RJ, Cheung NK. Rituximab therapy of lymphoma is enhanced by orally administered (1→3),(1→4)-D- β-glucan. Leuk Res 2005;29:679-83.
14. LeBlanc BW, Albina JE, Reichner JS. The effect of PGG-β-glucan on neutrophil chemotaxis in vivo. J Leukoc Biol 2006;79:667-75.
15. Tsikitis VL, Albina JE, Reichner JS. β-Glucan affects leukocyte navigation in a complex chemotactic gradient. Surgery 2004;136:384-9.
16. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 2003;40:109-23.
17. Liu J, Miwa T, Hilliard B, et al. The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med 2005;201:567-77.
18. Heeger PS, Lalli PN, Lin F, et al. Decay-accelerating factor modulates induction of T cell immunity. J Exp Med 2005;201:1523-30.
19. Lublin DM, Atkinson JP. Decay-accelerating factor: biochemistry, molecular biology, and function. Annu Rev Immunol 1989;7:35-58.
20. Harris CL, Lublin DM, Morgan BP. Efficient generation of monoclonal antibodies for specific protein domains using recombinant immunoglobulin fusion proteins: pitfalls and solutions. J Immunol Methods 2002;268:245-58.
21. Solly K, Wang X, Xu X, Strulovici B, Zheng W. Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays. Assay Drug Dev Technol 2004;2:363-72.
22. Gordon MS, Matei D, Aghajanian C, et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006;24:4324-32.
23. Kumar Pal S, Pegram M. Targeting HER2 epitopes. Semin Oncol 2006;33:386-91.
24. Govindan R. Cetuximab in advanced non-small cell lung cancer. Clin Cancer Res 2004;10:4241-4s.
25. Binder R, Kress A, Kan G, Herrmann K, Kirschfink M. Neutrophil priming by cytokines and vitamin D binding protein (Gc-globulin): impact on C5a-mediated chemotaxis, degranulation and respiratory burst. Mol Immunol 1999;36:885-92.
26. Jha P, Sohn JH, Xu Q, et al. Suppression of complement regulatory proteins (CRPs) exacerbates experimental autoimmune anterior uveitis (EAAU). J Immunol 2006;176:7221-31.
27. Lin F, Kaminski HJ, Conti-Fine BM, et al. Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J Clin Invest 2002;110:1269-74.
28. Lin F, Emancipator SN, Salant DJ, Medof ME. Decay-accelerating factor confers protection against complement-mediated podocyte injury in acute nephrotoxic nephritis. Lab Invest 2002;82:563-9.
29. Gelderman KA, Tomlinson S, Ross GD, Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 2004;25:158-64.
30. Niehans GA, Cherwitz DL, Staley NA, Knapp DJ, Dalmasso AP. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am J Pathol 1996;149:129-42.
31. Watson NF, Durrant LG, Madjd Z, et al. Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients. Cancer Immunol Immunother 2006;55:973-80.
32. Madjd Z, Durrant LG, Pinder SE, et al. Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)? Cancer Immunol Immunother 2005;54:149-56.
33. Bjorge L, Hakulinen J, Wahlstrom T, Matre R, Meri S. Complement- regulatory proteins in ovarian malignancies. Int J Cancer 1997;70:14-25.
34. Harris CL, Spiller OB, Morgan BP. Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities. Immunology 2000;100:462-70.
35. Rees MA, Butler AJ, Negus MC, Davies HF, Friend PJ. Classical pathway complement destruction is not responsible for the loss of human erythrocytes during porcine liver perfusion. Transplantation 2004;77:1416-23.
36. Liszewski MK, Leung MK, Schraml B, Goodship TH, Atkinson JP. Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndrome. Mol Immunol 2007;44:1559-68.
37. Barilla-LaBarca ML, Liszewski MK, Lambris JD, Hourcade D, Atkinson JP. Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells. J Immunol 2002;168:6298-304.
38. Shin ML, Hansch G, Hu VW, Nicholson-Weller A. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9. J Immunol 1986;136:1777-82.
39. Ziller F, Macor P, Bulla R, et al. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement- regulatory proteins CD55 and CD59. Eur J Immunol 2005;35:2175-83.
40. Terui Y, Sakurai T, Mishima Y, et al. Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab. Cancer Sci 2006;97:72-9.
41. Cheung NK, Walter EI, Smith-Mensah WH, et al. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest 1988;81:1122-8.
42. Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001;114:800-9.
43. Gelderman KA, Lam S, Sier CF, Gorter A. Crosslinking tumor cells with effector cells via CD55 with a bispecific mAb induces β-glucan-dependent CR3-dependent cellular cytotoxicity. Eur J Immunol 2006;36:977-84.
44. Gelderman KA, Kuppen PJ, Okada N, Fleuren GJ, Gorter A. Tumor-specific inhibition of membrane-bound complement regulatory protein Crry with bispecific monoclonal antibodies prevents tumor outgrowth in a rat colorectal cancer lung metastases model. Cancer Res 2004;64:4366-72.
45. Ravindranath NM, Shuler C. Expression of complement restriction factors (CD46, CD55 and CD59) in head and neck squamous cell carcinomas. J Oral Pathol Med 2006;35:560-7.